FAKTOR OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - BOERSE MUENCHEN 20:46:14 31/05/2024 BST | ||
| 7.37 EUR | -16.44% |
|
| 1 month | -54.70% | ||
| 3 months | -36.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 7.37 | -16.44% |
| 30/05/24 | 8.82 | +1.26% |
| 29/05/24 | 8.71 | +5.58% |
| 28/05/24 | 8.25 | +14.42% |
| 27/05/24 | 7.21 | -3.99% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 08:46 pm
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD33LG |
| ISIN | DE000HD33LG9 |
| Date issued | 27/02/2024 |
| Strike | 531.7 $ |
| Maturity | Unlimited |
| Parity | 10.1 : 1 |
| Emission price | 10.44 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 17.3 € |
|---|---|
| Lowest since issue | 7.16 € |
| Spread | 0.02 € |
| Spread % | 0.27% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Certificates
- Certificat
